





Abstract

Background: The purpose of this study was to evaluate the effect of the use of the... (The following text is severely distorted and illegible due to heavy noise and artifacts.)





References

1. Jackman DM, Johnson BE (2005) Small-cell lung cancer 366: 1385-1396.
2. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. *N Engl J Med* 346: 85-91.
3. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, et al. (2007) Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. *Br J Cancer* 97: 162-169.
4. Minegishi Y, Kuribayashi H, Kitamura K, Mizutani H, Kosaihiira S, et al. (2011) The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. *J Thorac Oncol* 6: 801-807.
5. Fujimoto D, Shimizu R, Kato R, Sato Y, Kogo M, et al. (2015) Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease. *Anticancer Res* 35: 6261-6266.
6. Enomoto Y, Inui N, Imokawa S, Karayama M, Hasegawa H, et al. (2015) Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. *Cancer Chemother Pharmacol* 76: 499-505.
7. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, et al. (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. *J Thorac Oncol* 6: 1242-1246.
8. Raghu G, Rochweg B, Zhang Y, Garcia CA, Azuma A, et al. (2015) An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care* 192: 3-19.
9. Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, et al. (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. *J Clin Oncol* 26: 5401-5406.
10. Mouri A, Yamaguchi O, Miyauchi S, Shiono A, Utsugi H, et al. (2019) Combination therapy with carboplatin and paclitaxel for small cell lung cancer. *Respir Investig* 57: 34-39.
11. Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, et al. (2016) Amrubicin for relapsed small-cell lung cancer: A systematic review and meta-analysis of 803 patients.
12. Yoh K, Kenmotsu H, Yamaguchi Y, Kubota K, Ohmatsu H, et al. (2010) Severe interstitial lung disease associated with amrubicin treatment. *J Thorac Oncol* 5: 1435-1438.
- 13.

-
18. Sugiyama K, Kogure Y, Torii A, Shiraishi K, Yamada A, et al. (2019) Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer: Retrospective single-institution observational study.
 19. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T (2006) Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer. *Cancer Chemother Pharmacol* 58: 86-90.
 20. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, et al. (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 30: 2055-2062.
 21. Usui Y, Usui Y, Kenmotsu H, Mori K (2018) A multicenter single-arm phase II study of nab-paclitaxel/carboplatin for non-small cell lung cancer patients with interstitial lung disease. *Annals of Oncology* 29: 493-547.
 22. Nasu S, Suzuki H, Moriizumi K, Hara Y, Tanaka S, et al. (2019) Re-challenge chemotherapy in patients with sensitive relapse small-cell lung cancer and interstitial lung disease. *J Thorac Dis* 11: 514-520.
 23. Enomoto Y, Inui N, Imokawa S, Karayama M, Hasegawa H, et al. (2015) Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. *Cancer Chemother Pharmacol* 76: 499-505.